Loading company…
Mozart Therapeutics develops biologics for autoimmune diseases.
Mozart Therapeutics is developing CD8 Treg modulators for autoimmune diseases, including candidates MTX-101 and MTX-201. Founded in 2020, the company raised USD 25.000 mn in Series A funding on June 7, 2023, with participation from Pfizer Venture Investments and AbbVie Biotech Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in